TESLASCAN Drug Patent Profile

When do Teslascan patents expire, and when can generic versions of Teslascan launch?

Teslascan is a drug marketed by Ic Targets and is included in one NDA.

The generic ingredient in TESLASCAN is mangafodipir trisodium. Additional details are available on the mangafodipir trisodium profile page.

Summary for TESLASCAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1
DailyMed Link:	TESLASCAN at DailyMed

Recent Clinical Trials for TESLASCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Egetis Therapeutics	Phase 2
PledPharma AB	Phase 2

See all TESLASCAN clinical trials

US Patents and Regulatory Information for TESLASCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997		DISCN	No	No

Expired US Patents for TESLASCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997	5,223,243
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997	4,647,447
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997	5,091,169
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997	4,992,554

International Patents for TESLASCAN

See the table below for patents covering TESLASCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	66368	Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
Canada	1240679	SELS COMPLEXES PARAMAGNETIQUES, PROCEDE DE PREPARATION ET UTILISATION DANS LES DIAGNOSTICS PAR RMN (PARAMAGNETIC COMPLEX SALTS, THEIR PREPARATION, AND THEIR USE IN NMR-DIAGNOSTICS)
Singapore	30569
South Africa	8205313

Supplementary Protection Certificates for TESLASCAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0290047	97C0108	Belgium		PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
0290047	67/1997	Austria		PRODUCT NAME: MANGAFODIPIR; REGISTRATION NO/DATE: SG(97)D/3940 19970522
0071564	SPC/GB93/060	United Kingdom
0290047	SPC/GB97/078	United Kingdom		PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522

TESLASCAN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for TESLASCAN

Introduction to TESLASCAN

TESLASCAN, containing the active substance mangafodipir trisodium, is a contrast medium used in magnetic resonance imaging (MRI) to enhance the visibility of lesions in the liver and pancreas. It is particularly useful for detecting liver cancer or cancer that has metastasized to the liver from other parts of the body[1][4].

Clinical Use and Indications

TESLASCAN is administered as a single intravenous infusion, with the dose calculated based on the patient's body weight. It is used to differentiate between normal and abnormal tissue, aiding in the diagnosis of liver and pancreatic lesions. The enhancement of imaging starts 15 to 20 minutes after the infusion and lasts for about 4 hours[1].

Market Demand for Diagnostic Imaging Agents

The demand for diagnostic imaging agents like TESLASCAN is driven by the increasing incidence of cancer and the need for accurate diagnostic tools. The global market for contrast agents is growing due to advancements in imaging technologies and the expanding use of MRI in various medical specialties.

Competitive Landscape

The market for MRI contrast agents is competitive, with several other products available. However, TESLASCAN's specificity for liver and pancreatic lesions gives it a niche position. The competitive landscape includes other manganese-based and gadolinium-based contrast agents, each with their own indications and market shares.

Regulatory Environment

TESLASCAN has been approved by regulatory bodies such as the European Medicines Agency (EMA) for its specific indications. Compliance with regulatory requirements is crucial for maintaining market presence. Any changes in regulatory standards or the approval of new competitors can impact the market dynamics[1].

Clinical Trials and Studies

The efficacy and safety of TESLASCAN have been evaluated in several clinical trials involving over 600 patients. These studies have demonstrated its effectiveness in enhancing MRI images of liver lesions, which is a critical factor in its market acceptance[1].

Safety and Adverse Effects

While TESLASCAN is generally well-tolerated, it can cause adverse effects such as chest pain, dizziness, and hypersensitivity reactions in some patients. The safety profile is an important consideration in the market, as it influences prescribing decisions and patient compliance[4].

Pharmacokinetics and Pharmacodynamics

The pharmacokinetics of TESLASCAN involve the rapid distribution and elimination of manganese, with most of the dose eliminated through urine and feces. Understanding these dynamics is essential for optimizing dosing and minimizing adverse effects[4].

Financial Performance of Pharmaceutical Companies

The financial performance of companies producing diagnostic imaging agents like TESLASCAN can be influenced by various factors, including sales volume, pricing strategies, and competition. However, TESLASCAN itself is not directly associated with the financial performance of major companies like Tesla, Inc., which is a separate entity involved in the automotive and energy sectors[2].

Revenue Streams and Pricing

The revenue generated by TESLASCAN is tied to its prescription volume and pricing. The cost of the drug is influenced by production costs, regulatory approvals, and market competition. Hospitals and healthcare providers often negotiate prices with pharmaceutical companies, which can impact the drug's profitability.

Market Growth and Projections

The market for diagnostic imaging agents is expected to grow due to increasing healthcare expenditures and the rising incidence of diseases that require advanced diagnostic tools. However, specific growth projections for TESLASCAN would depend on its market share, competition, and the overall demand for MRI contrast agents.

Challenges and Opportunities

Challenges for TESLASCAN include competition from other contrast agents, regulatory hurdles, and the need for continuous clinical evidence to support its use. Opportunities lie in expanding its indications, improving its safety profile, and increasing its market penetration through effective marketing and distribution strategies.

Key Takeaways

• TESLASCAN is a specialized MRI contrast agent for liver and pancreatic lesions.
• Its market demand is driven by the need for accurate diagnostic tools in oncology.
• The drug's safety profile and regulatory approvals are critical for its market presence.
• Financial performance is influenced by sales volume, pricing, and competition.
• The market for diagnostic imaging agents is expected to grow, offering opportunities for TESLASCAN.

FAQs

Q: What is TESLASCAN used for?

TESLASCAN is used as a contrast medium in MRI to detect lesions in the liver and pancreas, particularly for diagnosing liver cancer or cancer that has spread to the liver.

Q: How is TESLASCAN administered?

TESLASCAN is administered as a single intravenous infusion at a dose of 0.5 ml per kilogram body weight, with the rate of infusion varying depending on whether it is for liver or pancreatic imaging.

Q: What are the common adverse effects of TESLASCAN?

Common adverse effects include chest pain, dizziness, hot flushes, hypersensitivity reactions, and other mild to moderate symptoms.

Q: Is TESLASCAN approved by regulatory bodies?

Yes, TESLASCAN has been approved by the European Medicines Agency (EMA) for its specified indications.

Q: How does TESLASCAN work?

TESLASCAN works by releasing manganese, which interacts with water molecules in the body to enhance the signal in MRI scans, allowing for better differentiation between normal and abnormal tissue.

Sources:

1. European Medicines Agency. TESLASCAN, INN-mangafodipir - European Medicines Agency.
2. Marketscreener. Tesla, Inc.: Financial Data Forecasts Estimates and Expectations.
3. Aprea Therapeutics. SEC Filing | Aprea Therapeutics.
4. Health Canada. PRODUCT MONOGRAPH TESLASCAN (mangafodipir trisodium) Injection.*